• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by InflaRx N.V.

    12/20/24 8:01:01 AM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IFRX alert in real time by email
    6-K 1 ef20040227_6k.htm 6-K
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 6-K

    Report of Foreign Private
    Issuer Pursuant to Rule
    13a-16 or 15d-16 of the
    Securities Exchange Act
    of 1934
    For the month of December 2024
    Commission File
    Number: 001-38283

    InflaRx N.V.

    Winzerlaer Str. 2
    07745 Jena,
    Germany
    (+49) 3641508180

    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F  ☐



    INCORPORATION BY REFERENCE

    On December 20, 2024, InflaRx N.V. (the “Company”) issued a press release titled “InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904”.

    The Company announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (“CSU”) and hidradenitis suppurativa (“HS”), investigating the Company’s oral C5aR inhibitor, INF904. The Phase 2a trial is a multi-center, open-label study expected to include a total of 75 patients with moderate-to-severe CSU and moderate-to-severe HS. The trial will evaluate multiple INF904 dosing regimens over four weeks of treatment to generate additional safety and pharmacokinetic data and to provide signs of clinical benefit. As previously disclosed, this basket study is utilizing a commercially viable formulation of INF904, providing a range of drug exposures comparable to the reported levels in the Phase 1 study. After the four-week treatment period, patients will be followed for an additional four weeks. Data from this study are expected in the summer of 2025, with a goal of informing the design of a larger, longer-term Phase 2b study by year-end 2025.

    This report on Form 6-K (the “Report”) shall be deemed to be incorporated by reference into (i) the registration statements on Form S-8 (File No. 333-221656 and 333-240185) and (ii) the registration statement on Form F-3 (File No. 333-273058) of the Company and to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

    A copy of the press release is attached as Exhibit 99.1 to this Report. Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

    FORWARD-LOOKING STATEMENTS

    This Report contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this Report and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.


    EXHIBIT INDEX

    Exhibit No.
    Description
    99.1
    Press Release, dated December 20, 2024


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


    INFLARX N.V.
    Date: December 20, 2024
       

    By:
    /s/ Niels Riedemann

     
    Name: Niels Riedemann

     
    Title: Chief Executive Officer



    Get the next $IFRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IFRX

    DatePrice TargetRatingAnalyst
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2023$8.00Neutral → Buy
    Guggenheim
    2/28/2022Buy → Neutral
    Guggenheim
    11/8/2021$14.00 → $15.00Strong Buy
    Raymond James
    10/28/2021$14.00Outperform → Strong Buy
    Raymond James
    8/6/2021$11.00 → $10.00Outperform
    Raymond James
    8/6/2021$2.80 → $2.50Underperform
    Credit Suisse
    More analyst ratings

    $IFRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

      Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline addressing multiple sizable marketsInterim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG), to determine trial size adaptation or futility, remains on schedule with a recommendation expected to be announced at the end of May to early JuneTopline data for INF904 Phase 2a trial in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025Cash, cash equivalents and marketable securities totaled

      5/7/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report First Quarter 2025 Results on May 7, 2025

      JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory media

      4/30/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

      Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904, with topline data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025Multiple data presentations at AAD 2025 highlighting the potential of vilobelimab in reducing systemic inflammationCash, cash equivalents and marketable securities of €5

      3/20/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Financials

    Live finance-specific insights

    See more
    • InflaRx to Report First Quarter 2025 Results on May 7, 2025

      JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory media

      4/30/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

      JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned. InflaRx also announced that it will participate in two investor conferences. Details are as follows: Leerink Global Healthcare ConferenceMarch 9 - 12, 2025 in Miami Beach, FL InflaRx will conduct a fireside chat at the conference on March 10 at 10:40 AM ET and will participate in one-on-one-investor meetings. A link to regis

      2/25/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

      JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its third quarter 2024 financial and operating results on Friday, November 8, 2024, before the market opens. No conference call is planned. In addition, InflaRx will participate in the following investor event: Guggenheim Securities Inaugural Healthcare Innovation ConferenceNovember 11-13, 2024, Boston, MAFireside chat: November 11th, 11:00 am ET A link to register for the fireside chat live stream and its replay is available here. The company will also participa

      10/31/24 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on InflaRx with a new price target

      Cantor Fitzgerald initiated coverage of InflaRx with a rating of Overweight and set a new price target of $10.00

      4/29/25 8:10:45 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx upgraded by Guggenheim with a new price target

      Guggenheim upgraded InflaRx from Neutral to Buy and set a new price target of $8.00

      4/5/23 11:33:25 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx downgraded by Guggenheim

      Guggenheim downgraded InflaRx from Buy to Neutral

      2/28/22 11:38:01 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Leadership Updates

    Live Leadership Updates

    See more
    • InflaRx Appoints Jan Medina as Head of Investor Relations

      JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "We are delighted to welcome Jan to our team. His experience, proven track record and deep network with investors and capital mark

      2/22/24 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

      Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical development of InflaRx's portfolio of C5a/C5aR inhibitors JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affai

      6/28/23 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by InflaRx N.V.

      SC 13G - InflaRx N.V. (0001708688) (Subject)

      4/24/23 4:47:08 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by InflaRx N.V.

      SC 13G - InflaRx N.V. (0001708688) (Subject)

      4/17/23 4:00:10 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by InflaRx N.V. (Amendment)

      SC 13G/A - InflaRx N.V. (0001708688) (Subject)

      2/13/23 12:01:42 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    SEC Filings

    See more
    • SEC Form 6-K filed by InflaRx N.V.

      6-K - InflaRx N.V. (0001708688) (Filer)

      5/7/25 7:53:43 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by InflaRx N.V.

      6-K - InflaRx N.V. (0001708688) (Filer)

      4/24/25 5:00:36 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by InflaRx N.V.

      6-K - InflaRx N.V. (0001708688) (Filer)

      4/3/25 7:31:25 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care